Skip to main content
Erschienen in: Pathology & Oncology Research 2/2011

01.06.2011 | Research

Upregulation of Twist in Gastric Carcinoma Associated with Tumor Invasion and Poor Prognosis

verfasst von: Guo-Qing Ru, Hui-Ju Wang, Wen-Jun Xu, Zhong-Sheng Zhao

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Tumor invasion and metastasis are the most common causes of death in gastric carcinoma. Twist, a transcription factor of the basic helix-loop-helix class, reportedly regulates cancer metastasis and induces epithelial-mesenchymal transition (EMT). We evaluated the expression of Twist and its effect on cell migration in gastric carcinoma (GC). Twist expression was detected by real-time quantitative RT-PCR in gastric tumor tissue, metastatic lymph nodes and normal gastric tissue from 47 gastric carcinoma patients who had undergone gastrectomies with radical lymph node dissections without preoperative treatment. Twist expression was also analyzed immunohistochemically in 436 gastric cancer cases. GC tumor tissue and metastatic lymph nodes was upregulated compared with normal gastric mucosa (P < 0.05). Twist protein expression differed significantly among gastric tumor tissue, matched normal gastric mucosa, and lymph nodes (P < 0.05) In stages I, II, and III, 5-year survival rates of patients with high Twist expression were significantly lower than in patients with low expression (P < 0.05). In stage IV, Twist expression did not correlate with 5-year survival rates (P = 0.07). Further multivariate analysis suggested that depth of invasion, lymph-node and distant metastases, TNM stage, and up-regulation of TWIST were independent prognostic indicators for GC. Twist expression in gastric cancer is associated significantly with lymph-node and distant metastases, and poor prognosis. Twist may be a useful marker for the development, progression and metastasis of GC.
Literatur
1.
Zurück zum Zitat Zhan WH, Han FH (2008) Surgical therapy of gastric cancer in china. J Pract Oncol 23:91–93 Zhan WH, Han FH (2008) Surgical therapy of gastric cancer in china. J Pract Oncol 23:91–93
2.
Zurück zum Zitat Eccles SA, Welch DR (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet 369:1742–1757PubMedCrossRef Eccles SA, Welch DR (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet 369:1742–1757PubMedCrossRef
3.
Zurück zum Zitat Gilles C, Thompson EW (1996) The epithelial-to-mesenchymal transition and metastatic progression in carcinoma. Breast J 2:83–96CrossRef Gilles C, Thompson EW (1996) The epithelial-to-mesenchymal transition and metastatic progression in carcinoma. Breast J 2:83–96CrossRef
4.
5.
Zurück zum Zitat Monk M, Holding C (2001) Human embryonic genes re-expressed in cancer cells. Oncogene 20:8085–8091PubMedCrossRef Monk M, Holding C (2001) Human embryonic genes re-expressed in cancer cells. Oncogene 20:8085–8091PubMedCrossRef
6.
Zurück zum Zitat Bates RC, Mercurio AM (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 4:365–370PubMedCrossRef Bates RC, Mercurio AM (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 4:365–370PubMedCrossRef
7.
Zurück zum Zitat Xue C, Plieth D, Venkov C et al (2003) The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 63:3386–3394PubMed Xue C, Plieth D, Venkov C et al (2003) The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 63:3386–3394PubMed
8.
Zurück zum Zitat Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelia-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131–142PubMedCrossRef Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelia-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131–142PubMedCrossRef
9.
Zurück zum Zitat Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740–746PubMedCrossRef Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740–746PubMedCrossRef
10.
Zurück zum Zitat Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nature Rev 2:442–454CrossRef Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nature Rev 2:442–454CrossRef
11.
Zurück zum Zitat Yook JI, Li XY, Ota I et al (2005) Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem 280:11740–11748PubMedCrossRef Yook JI, Li XY, Ota I et al (2005) Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem 280:11740–11748PubMedCrossRef
12.
Zurück zum Zitat Zhou BP, Deng J, Xia W et al (2004) Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nature Cell Biol 6:931–940PubMedCrossRef Zhou BP, Deng J, Xia W et al (2004) Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nature Cell Biol 6:931–940PubMedCrossRef
13.
Zurück zum Zitat Cheng GZ, Zhang W, Wang LH (2008) Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res 68:957–960PubMedCrossRef Cheng GZ, Zhang W, Wang LH (2008) Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res 68:957–960PubMedCrossRef
14.
Zurück zum Zitat Yang J, Mani SA, Donaher JL et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927–939PubMedCrossRef Yang J, Mani SA, Donaher JL et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927–939PubMedCrossRef
15.
Zurück zum Zitat Yang J, Mani SA, Weinberg RA (2006) Exploring a new twist on tumor metastasis. Cancer Res 66:4549–4552PubMedCrossRef Yang J, Mani SA, Weinberg RA (2006) Exploring a new twist on tumor metastasis. Cancer Res 66:4549–4552PubMedCrossRef
16.
Zurück zum Zitat Lee TK, Poon RT, Yuen AP et al (2006) Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12:5369–5376PubMedCrossRef Lee TK, Poon RT, Yuen AP et al (2006) Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12:5369–5376PubMedCrossRef
17.
Zurück zum Zitat Yang Z, Zhang X, Gang H et al (2007) Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Comm 358:925–930PubMedCrossRef Yang Z, Zhang X, Gang H et al (2007) Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Comm 358:925–930PubMedCrossRef
18.
Zurück zum Zitat Lee HS, Lee HK, Kim HS et al (2003) Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 200:39–46PubMedCrossRef Lee HS, Lee HK, Kim HS et al (2003) Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 200:39–46PubMedCrossRef
19.
Zurück zum Zitat Lee HS, Lee HK, Kim HS et al (2001) MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer 92:1427–1434PubMedCrossRef Lee HS, Lee HK, Kim HS et al (2001) MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer 92:1427–1434PubMedCrossRef
20.
Zurück zum Zitat Zhang D, Salto-Tellez M, Putti TC et al (2003) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16:79–84PubMedCrossRef Zhang D, Salto-Tellez M, Putti TC et al (2003) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16:79–84PubMedCrossRef
21.
Zurück zum Zitat Lee HS, Cho SB, Lee HE et al (2007) Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res 13:4154–4163PubMedCrossRef Lee HS, Cho SB, Lee HE et al (2007) Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res 13:4154–4163PubMedCrossRef
22.
Zurück zum Zitat Kolev Y, Uetake H, Iida S et al (2007) Prognostic significance of VEGF expression in correlation with COX-2, microvessel density and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncology 14:2738–2747CrossRef Kolev Y, Uetake H, Iida S et al (2007) Prognostic significance of VEGF expression in correlation with COX-2, microvessel density and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncology 14:2738–2747CrossRef
23.
Zurück zum Zitat Mizokami K, Kakeji Y, Oda S et al (2006) Clinicopathologic significance of hypoxia-inducible factor 1 alpha overexpression in gastric carcinomas. J Surg Oncology 94:149–154CrossRef Mizokami K, Kakeji Y, Oda S et al (2006) Clinicopathologic significance of hypoxia-inducible factor 1 alpha overexpression in gastric carcinomas. J Surg Oncology 94:149–154CrossRef
24.
Zurück zum Zitat Song LB, Liao WT, Mai HQ et al (2006) The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett 242:258–265PubMedCrossRef Song LB, Liao WT, Mai HQ et al (2006) The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett 242:258–265PubMedCrossRef
25.
Zurück zum Zitat Kolev Y, Uetake H, Iida S et al (2007) Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 14:2738–2747PubMedCrossRef Kolev Y, Uetake H, Iida S et al (2007) Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 14:2738–2747PubMedCrossRef
26.
Zurück zum Zitat Chou YY, Jeng YM, Lee TT et al (2007) Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 14:2748–2758PubMedCrossRef Chou YY, Jeng YM, Lee TT et al (2007) Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 14:2748–2758PubMedCrossRef
27.
Zurück zum Zitat Chen ZF, Behringer RR (1995) Twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev 9:686–699PubMedCrossRef Chen ZF, Behringer RR (1995) Twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev 9:686–699PubMedCrossRef
28.
Zurück zum Zitat Leptin M (1991) Twist and snail as positive and negative regulators during Drosophila mesoderm development. Genes Dev 5:1568–1576PubMedCrossRef Leptin M (1991) Twist and snail as positive and negative regulators during Drosophila mesoderm development. Genes Dev 5:1568–1576PubMedCrossRef
29.
Zurück zum Zitat Maestro R, Dei Tos AP, Hamamori Y et al (1999) Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13:2207–2217PubMedCrossRef Maestro R, Dei Tos AP, Hamamori Y et al (1999) Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13:2207–2217PubMedCrossRef
30.
Zurück zum Zitat Valsesia-Wittmann S, Magdeleine M, Dupasquier S et al (2004) Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 6:625–630PubMedCrossRef Valsesia-Wittmann S, Magdeleine M, Dupasquier S et al (2004) Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 6:625–630PubMedCrossRef
31.
Zurück zum Zitat Yang J, Mani SA, Donaher JL et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927–939PubMedCrossRef Yang J, Mani SA, Donaher JL et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927–939PubMedCrossRef
32.
Zurück zum Zitat Rosivatz E, Becker I, Specht K et al (2002) Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 161:1881–1891PubMedCrossRef Rosivatz E, Becker I, Specht K et al (2002) Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 161:1881–1891PubMedCrossRef
33.
Zurück zum Zitat Martin TA, Goyal A, Watkins G et al (2005) Expression of the transcription factors snail, slug, and Twist and their clinical significance in human breast cancer. Ann Surg Oncol 12:488–496PubMedCrossRef Martin TA, Goyal A, Watkins G et al (2005) Expression of the transcription factors snail, slug, and Twist and their clinical significance in human breast cancer. Ann Surg Oncol 12:488–496PubMedCrossRef
34.
Zurück zum Zitat Hoek K, Rimm DL, Williams KR et al (2004) Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64:5270–5282PubMedCrossRef Hoek K, Rimm DL, Williams KR et al (2004) Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64:5270–5282PubMedCrossRef
35.
Zurück zum Zitat Watanabe O, Imamura H, Shimizu T et al (2004) Expression of twist and wnt in human breast cancer. Anticancer Res 24:3851–3856PubMed Watanabe O, Imamura H, Shimizu T et al (2004) Expression of twist and wnt in human breast cancer. Anticancer Res 24:3851–3856PubMed
36.
Zurück zum Zitat Zi X, Guo Y, Simoneau AR et al (2005) Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 65:9762–9770PubMedCrossRef Zi X, Guo Y, Simoneau AR et al (2005) Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 65:9762–9770PubMedCrossRef
37.
Zurück zum Zitat Guo Y, Zi X, Koontz Z et al (2007) Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res 25:964–971PubMedCrossRef Guo Y, Zi X, Koontz Z et al (2007) Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res 25:964–971PubMedCrossRef
38.
Metadaten
Titel
Upregulation of Twist in Gastric Carcinoma Associated with Tumor Invasion and Poor Prognosis
verfasst von
Guo-Qing Ru
Hui-Ju Wang
Wen-Jun Xu
Zhong-Sheng Zhao
Publikationsdatum
01.06.2011
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2011
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-010-9332-0

Weitere Artikel der Ausgabe 2/2011

Pathology & Oncology Research 2/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.